Chlorin e6 (Ce6) is a second-generation photosensitizer with antitumor activity when used in conjunction with irradiation.
CAS：19660-77-6
分子式：C34H36N4O6
分子量：596.7
纯度：98%
存储：Store at -20°C

Background:

Chlorin e6 (Ce6) is a second-generation photosensitizer with antitumor activity when used in conjunction with irradiation. In a mouse model of implanted fibrosarcoma, Ce6 (2.5-10 mg/kg, i.v. with irradiation at 50-200 J/cm2) led to complete tumor loss following varying levels of irradiation.[1] A formulation including Ce6 was tested in a Phase I clinical study for patients with bronchogenic early superficial squamous cell carcinoma with positive results (40 mg/m2, i.v. with laser irradiation at 100 J/cm2).[2] The same dosing paradigm in a Phase II clinical trial for early stage lung cancer patients led to a complete response in 82.9% of patients.[3] Ce6 has been examined as a nanotechnology drug delivery tool.[4]

Reference:
[1]. Katsumi, T.A., Aizawa, K., Kuroiwa, Y., et al. Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspartyl chlorin E6. Photochem. Photobiol. 64(4), 671-675 (1996).
[2]. Furukawa, K., Okunaka, T., and Tsuchida, T. A phase I clinical study of photodynamic therapy for early stage lung carcinoma using ME2906 and a diode laser system. Porphyrins. 7, 199-206 (1998).
[3]. Kato, H., Furukawa, K., Sato, M., et al. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer 42(1), 103-111 (2003).
[4]. Chai, S., Guo, Y., Zhang, Z., et al. Cyclodextrin-gated mesoporous silica nanoparticles as drug carriers for red light-induced drug release. Nanotechnology 28(14), 145101 (2017).